The Pharma Data

DECEMBER 21, 2020

military scientists to determine if it might be resistant to vaccines. The deal also includes more than $30 billion to acquire and distribute coronavirus vaccines and $27 billion for testing and state health care programs. Higher flu vaccination rates are one reason why flu cases are way down in the United States, experts say.

Vaccine 52

Vaccine Packaging Laboratories Virus 52

The Pharma Data

NOVEMBER 9, 2020

DAEGU, KOREA, November 09, 2020 /24-7PressRelease/ — South Korean religious group Shincheonji Church of Jesus has announced their third convalescent plasma donation drive to take place for 3 weeks starting November 16th at an Indoor Athletics Center in Daegu. Approximately 4,000 members of the group are expected to participate.

Treatment 145

Treatment Vaccine Disease 145

The Pharma Data

NOVEMBER 10, 2020

AHA: Young Adults With CVD Have Low Flu Vaccination Rates. 10, 2020 — Many young adults with cardiovascular disease (CVD) do not receive influenza vaccination, according to a study presented at the American Heart Association Scientific Sessions 2020, held virtually from Nov. © 2020 HealthDay.

Vaccine 52

Vaccine Disease Research 52

The Pharma Data

APRIL 14, 2021

The product’s early Marek’s disease onset of immunity from five days of age provides full protection of broilers, layers and breeders against the most virulent Marek’s disease virus strains. Its purpose is to provide poultry producers with cutting-edge technology in terms of Marek’s disease protection.

Vaccine 52

Vaccine Disease Virus Engineering 52

The Pharma Data

JANUARY 21, 2021

Percent of Kindergarteners Not Up to Date With MMR in 2019-2020. percent of kindergarteners were not up to date with measles, mumps, and rubella (MMR) vaccination and did not have an exemption in the 2019 to 2020 school year, according to research published in the Jan. The researchers found that vaccination coverage was 94.9,

Vaccine 52

Vaccine Disease Research 52

The Pharma Data

DECEMBER 31, 2020

Monthly News Roundup – December 2020. Moderna and Pfizer’s COVID-19 Vaccines Roll Out in Early Phase. Food and Drug Administration (FDA) issued Emergency Use Authorization for two COVID-19 vaccines: Pfizer-BioNTech’s BNT162b2 and Moderna’s mRNA-1273. The partial piece of the spike protein cannot cause COVID-19 disease.

FDA Approval 52

FDA Approval Vaccine FDA Treatment 52

The Pharma Data

DECEMBER 8, 2020

AstraZeneca (AZ) and the University of Oxford have presented new data from a “pooled analysis” of phase 3 trials evaluating COVID-19 vaccine AZD1222 at two different dose regimens, demonstrating an average efficacy of 70.4 The University of Oxford claims no vaccinated participants were hospitalized or suffered serious forms of the disease.

Vaccine 52

Vaccine Trials Hospitals Disease 52

The Pharma Data

DECEMBER 14, 2020

14, 2020 — The Pfizer-BioNTech COVID-19 vaccine has received the first emergency use authorization (EUA) for a COVID-19 vaccine in the United States. Centers for Disease Control and Prevention Director Robert R. The vaccine is administered in two doses three weeks apart. MONDAY, Dec. Redfield, M.D.,

Vaccine 52

Vaccine Nurses FDA Virus 52

The Pharma Data

NOVEMBER 18, 2020

19, 2020 /PRNewswire/ — OBI Pharma, Inc. These results will be presented by the lead investigators of OBI Pharma’s novel anti-Globo H therapeutic cancer vaccine, OBI-833. In addition, OBI-833 can elicit a beneficial immune response in NSCLC patients and had rendered some TKI-treated patients a durable stable disease status.

Vaccine 52

Vaccine Small Molecule Immune Response Hospitals 52

The Pharma Data

DECEMBER 17, 2020

Advisory Committee Votes to Recommend EUA for Moderna Vaccine. 17, 2020 — The Moderna COVID-19 vaccine received recommendation from a U.S. Food and Drug Administration advisory committee on Thursday, clearing the way for it to become the second COVID-19 vaccine to be granted emergency use authorization.

Vaccine 52

Vaccine Government Clinical Trials FDA 52

The Pharma Data

DECEMBER 8, 2020

8, 2020 — AstraZeneca’s COVID-19 vaccine is safe and effective, new data from late-stage trials shows. Overall, the vaccine protected against symptomatic disease in 70% of cases, according to a team led by researchers from Oxford University in England. TUESDAY, Dec. 8 in The Lancet.

Vaccine 52

Vaccine Trials Immune Response RNA 52

The Pharma Data

NOVEMBER 9, 2020

About One in Five Children Have Vaccine-Hesitant Parent. 9, 2020 — Parental vaccine hesitancy (VH) is reported for about 20 percent of children in the United States, according to a study published online Nov. © 2020 HealthDay. Posted: November 2020. Professional. MONDAY, Nov. 9 in Pediatrics. from the U.S.

Vaccine 52

Vaccine Disease Research 52

The Pharma Data

DECEMBER 11, 2020

11, 2020 — More than 15 million Americans have been infected by the COVID-19 virus, and many may be questioning whether they need to receive one of the two coronavirus vaccines now on the verge of approval from U.S. William Schaffner, a professor of infectious diseases at Vanderbilt University Medical Center in Nashville, Tenn.

Vaccine 52

Vaccine Immune Response Virus Trials 52

The Pharma Data

DECEMBER 22, 2020

22, 2020 — In very rare cases, some people have had severe allergic reactions after receiving the new COVID-19 vaccines, leading the American College of Allergy , Asthma, and Immunology (ACAAI) to issue updated guidance for Americans with allergies. © 2020 HealthDay. TUESDAY, Dec.

Vaccine 52

Vaccine Immune Response Treatment Disease 52

The Pharma Data

NOVEMBER 16, 2020

Moderna Vaccine Shows 94.5 16, 2020 — Moderna Inc. announced on Monday that early results show its COVID-19 vaccine is 94.5 The researchers behind the vaccine said the results were far better than they had hoped. National Institute of Allergy and Infectious Diseases. © 2020 HealthDay. Professional.

Vaccine 52

Vaccine Research Disease 52

The Pharma Data

JUNE 29, 2021

Sanofi will invest approximately €400 million annually in a first-of-its kind vaccines mRNA Center of Excellence. “During the COVID-19 pandemic, mRNA technologies demonstrated potential to deliver new vaccines faster than ever before. . ” said Thomas Triomphe, Executive Vice President, Global Head of Sanofi Pasteur.

Vaccine 52

Vaccine Disease International Treatment 52

The Pharma Data

DECEMBER 19, 2020

20, 2020 02:44 UTC. Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines today announced that the U.S. 11 ACIP members voted in favor of the vaccine and 0 members voted against. We look forward to vaccinations of this important population starting this week.”. CAMBRIDGE, Mass.–(

Vaccine 52

Vaccine Long-Term Care Facilities FDA Licensing 52

The Pharma Data

NOVEMBER 29, 2020

AstraZeneca’s COVID-19 vaccine candidate is facing another potential delay as the company plans to undertake a new global clinical trial to confirm the vaccine’s 90 percent efficacy based on a one-and-a-half-dose regimen. The FDA’s vaccines advisory committee will meet on Dec. James Miessler.

Vaccine 52

Vaccine Trials FDA Clinical Trials 52

The Pharma Data

JUNE 26, 2021

Sanofi and Translate Bio initiate Phase 1 clinical trial of mRNA influenza vaccine. The trial will evaluate the safety and immunogenicity of a monovalent flu vaccine candidate coding for the hemagglutinin protein of the A/H3N2 strain of the influenza virus. JUNE 22 , 2021. We look forward to sharing initial results by year-end. ”. “

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52

DrugBaron

NOVEMBER 9, 2020

The first death unequivocally caused by COVID was reported to the world on January 11 th 2020 – that’s just 303 days ago (even if it feels like a lifetime away). Indeed, China has already licensed a vaccine, albeit without the data that would typically be required to support such an approval. But that cannot be the whole answer.

Vaccine 100

Vaccine Pharmaceutical Companies Government Pharmaceuticals 100

The Pharma Data

NOVEMBER 23, 2020

23, 2020 — The novel chimpanzee adenovirus-vectored vaccine, ChAdOx1 nCoV-19, is well tolerated, especially among older adults, according to a study published online Nov. During the study period, 13 serious adverse events occurred, none of which were considered to be related to the study vaccine. © 2020 HealthDay.

Vaccine 52

Vaccine Pharmaceutical Companies Pharmaceuticals Disease 52

The Pharma Data

DECEMBER 21, 2020

21, 2020 — A second COVID-19 vaccine is poised to be administered in the coming weeks after the U.S. Food and Drug Administration granted emergency use authorization (EUA) to the Moderna COVID-19 vaccine on Friday. The EUA allows for the vaccine to be administered to adults 18 years and older in two doses one month apart.

Vaccine 52

Vaccine FDA Hospitals Disease 52

The Pharma Data

JULY 8, 2021

People who receive mRNA COVID-19 vaccines are up to 91 percent less likely to develop the disease than those who are unvaccinated, according to a new nationwide study of eight sites, including Salt Lake City. Those who unfortunately got COVID-19 despite being vaccinated were still better off than those who didn’t.”

Vaccine 52

Vaccine Virus Nurses Hospitals 52

The Pharma Data

NOVEMBER 18, 2020

18, 2020 — Children should be included in clinical trials for a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine at the earliest stages, according to a letter from the president of the American Academy of Pediatrics (AAP), on behalf of more than 67,000 pediatricians and pediatric medical and surgical subspecialists.

Vaccine 52

Vaccine Trials Immune Response Virus 52

The Pharma Data

NOVEMBER 16, 2020

November 16, 2020 — An independent data and safety monitoring board (DSMB) overseeing the Phase 3 trial of the investigational COVID-19 vaccine known as mRNA-1273 reviewed trial data and shared its interim analysis with the trial oversight group on Nov. 37% of trial volunteers are from racial and ethnic minorities.

Clinical Trials 52

Clinical Trials Vaccine Trials FDA Approval 52

The Pharma Data

JANUARY 7, 2021

Anaphylaxis Cases/Million Doses of Pfizer-BioNTech COVID-19 Vaccine Reported. 23, 2020, researchers determined there were 21 cases of anaphylaxis (11.1 per million doses administered) after receipt of the first dose of the Pfizer-BioNTech COVID-19 vaccine in the United States, according to research published in the Jan.

Vaccine 52

Vaccine Research Disease Drugs 52

The Pharma Data

NOVEMBER 18, 2020

18, 2020 (American Heart Association News) — For people who have heart disease, getting a flu shot greatly reduces the risk of dying or developing serious heart-related complications, a new analysis shows. The Centers for Disease Control and Prevention recommends everyone over the age of 6 months be vaccinated for the flu.

Disease 52

Disease Vaccine Hospitals Research 52

The Pharma Data

JULY 15, 2021

FreVAX is an innovative intramuscular needle free vaccine injection device for pigs around weaning until the end of nursery. FreVAX intramuscular needle free device has been available since December 2020 to swine producers globally. We develop solutions and provide services to protect animals from disease and pain.

Vaccine 52

Vaccine Compliance Disease 52

The Pharma Data

JUNE 25, 2021

In the unprecedented context of at least 13 variants circulating within the study population subset assessed at this interim analysis, CVnCoV demonstrated an interim vaccine efficacy of 47% against COVID-19 disease of any severity and did not meet prespecified statistical success criteria. About CVnCoV. About CVnCoV.

Vaccine 52

Vaccine Trials Immune Response Virus 52

The Pharma Data

DECEMBER 30, 2020

30 December 2020 — AstraZeneca’s COVID-19 vaccine has been approved for emergency supply in the UK, with the first doses being released today so that vaccinations may begin early in the New Year. This is the first authorisation for this vaccine.

Vaccine 52

Vaccine Clinical Trials Virus Trials 52

The Pharma Data

NOVEMBER 30, 2020

30, 2020 (GLOBE NEWSWIRE) — Novavax, Inc. Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today provided an update on its COVID-19 vaccine program. Novavax will use vaccine material produced at commercial scale for this trial.

Clinical Development 52

Clinical Development Vaccine Clinical Trials Immune Response 52

The Pharma Data

DECEMBER 1, 2020

1, 2020 — Health care workers and people in nursing homes should be at the front of the line for upcoming COVID-19 vaccines, a U.S. Centers for Disease Control and Prevention advisory panel recommended Tuesday. In 2021, five to 10 million doses of vaccine are anticipated to ship each week. TUESDAY, Dec.

Long-Term Care Facilities 52

Long-Term Care Facilities Nurses Vaccine Pharmacy 52

The Pharma Data

MARCH 11, 2021

Sanofi Pasteur, the vaccines global business unit of Sanofi, and Translate Bio (NASDAQ: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company, today announced the start of the Phase 1/2 clinical trial for MRT5500, an mRNA vaccine candidate against SARS-CoV-2, the virus that causes COVID-19.

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52

Broad Institute

JANUARY 30, 2024

Bhattacharyya wears many coats today, splitting his time between the Broad and the infectious disease ward at MGH, where a diagnostic method he developed at Broad is now being tested to see if it helps patients quickly receive the best antibiotics for their infections.

Hospitals 137

Hospitals Virus Medical Schools Science 137

The Pharma Data

NOVEMBER 9, 2020

09, 2020 (GLOBE NEWSWIRE) — Novavax, Inc. Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for NVX-CoV2373, the Company’s COVID-19 vaccine candidate.

Vaccine 52

Vaccine FDA Clinical Trials Immune Response 52

The Pharma Data

JANUARY 25, 2021

In a surprise move, Merck announced that it is giving up on its two coronavirus vaccine candidates after seeing a subpar immune response and shifting its focus to a pair of investigational coronavirus treatments. 24, 2020 ). 28, 2020 ). The drugmaker’s decision coincides with a tightening of vaccine supplies in the U.S.

Vaccine 52

Vaccine Immune Response Trials Clinical Trials 52

The Pharma Data

NOVEMBER 23, 2020

23 November 2020 . Positive high-level results from an interim analysis of clinical trials of AZD1222 in the UK and Brazil showed the vaccine was highly effective in preventing COVID-19, the primary endpoint, and no hospitalisations or severe cases of the disease were reported in participants receiving the vaccine. .

Vaccine 52

Vaccine Virus Trials Clinical Trials 52